A “Malignant” Variant of Status Epilepticus

• DOI: 10.1001/archneur.62.9.1428
• Publication Date: 2005-09-12T20:23:51Z
• Authors: Martin Holtkamp; Jalal Othman; Katharina Buchheim; Florian Masuhr; Eva Schielke; Hartmut Meierkord
• Keywords: Refractory (planetary science); Autoimmune encephalitis

Background: Status epilepticus (SE) frequently does not respond to common first-line anticonvulsants.In a substantial portion of patients, administration anticonvulsant anesthetics is inevitable.Even this aggressive approach fails terminate SE in an undefined number cases.We have coined the term malignant for most severe variant SE.Objective: To assess frequency, risk factors, and inhospital outcome SE.Design: Retrospective cohort study.Setting: Neurologic intensive care unit large university hospital.Patients: Sample 35 episodes responding anticonvulsants 34 patients.Main Outcome Measures: Predictive prognostic features with persistent epileptic activity after high-dose compared remainder cases refractory failure firstline anticonvulsants.Results: that could be controlled by resulted 20% cases.Patients were significantly younger than patients (P=.03).Encephalitis was identified as independent factor (P =.008).Outcome poor, longer duration seizure (PϽ.001), stay neurologic (PϽ.001) hospital (P=.007), more functional dependency at discharge from =.04).Conclusions: Malignant rare anticonvulsants.The patient typically young suffers encephalitis.Such should treated aggressively early course prevent SE.